Show notes
This week, I had an insightful conversation with David Sans, PhD, FAARM, MBA, who heads healthcare investment banking at EF Hutton. We discussed the intricacies of different Public Offering strategies, including micro IPOs, which offer a unique avenue for biotech companies. David provides a deep perspective on the strategic implications of IPOs for biotech funding. He emphasized the importance of investor support and strategic banking partnerships, especially for micro IPOs. We also discussed the potential of AI in reshaping financial services and the future of outcome-based pricing models in investment. David's personal insights reveal the demanding yet rewarding nature of investment banking and highlight crucial aspects to consider for those pursuing a career in this field. Get David's recommended book: Barcelona, Catalonia: A View from the InsideLearn more about EF Hutton LLC!Link In with David!Connect with us!Link In with CarinaSubscribe here:AppleSpotifyGoogle PodcastRSS feedLearn more about Recruitomics ConsultingCheck out our reading listDownload our free startup resources guide to grow your biotech efficientlyIf you're on the job market, visit the Collaboratory Career Hub 00:00 Introduction to Biotech and Investment Banking00:48 David Sands' Background and Career Journey02:12 Transition from Biotech to Finance04:53 Understanding Micro IPOs06:37 Challenges and Strategies in Biotech IPOs16:38 The Role of the FDA in Biotech IPOs18:30 Understanding IPO Disparities18:42 Key Factors for a Successful IPO19:29 Aftermarket Support and Investor Relations20:59 The Role of Long-Term Investors21:34 Personal Investment Strategies22:29 Innovations in Financial Services24:40 Challenges for Biotech CEOs26:32 Career Path in Investment Banking28:50 Future of Financial Services and AI33:37 Book Recommendations and Closing Thoughts
